The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in Nonalcoholic Steatohepatitis (NASH) Treatment (FLINT) Trial

Trial Profile

The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in Nonalcoholic Steatohepatitis (NASH) Treatment (FLINT) Trial

Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Obeticholic acid (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Acronyms FLINT
  • Most Recent Events

    • 15 Sep 2017 Results of post-hoc analysis presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
    • 12 Jun 2017 Data from the retrospective analysis of this trial published in an Intercept Pharmaceuticals Media Release.
    • 12 Jun 2017 According to an Intercept Pharmaceuticals media release, data from the retrospective analysis of this trial were presented at the American Diabetes Association's 77th Scientific Sessions.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top